Daily Briefing – May 19: Oil cools but remains elevated, yields stay dangerous, Nvidia and retail earnings test the tape, while ONDS, Dominion and biotech FDA dates keep stock-specific action alive

The May 19 setup is slightly less panicked than Monday’s oil-driven tape, but it is not clean risk-on. Oil has eased after the latest Iran-related headlines, with Brent around the $110 area and U.S. crude near the $107 area, yet the bigger problem has not disappeared: energy is still high enough to keep inflation risk alive, Treasury yields remain close to uncomfortable levels, and growth stocks are still being judged against a higher-rate backdrop. U.S. futures are softer, global equities are mixed, and traders are entering a heavy earnings window where Nvidia remains the central AI sentiment test while Home Depot, Lowe’s, Target, Walmart, TJX, Deere and other consumer-facing names give the market a real-time read on household demand, housing pressure and margin resilience. In single-stock news, the NextEra-Dominion deal keeps the AI power-demand theme alive far beyond semiconductors, Regeneron is under pressure after a melanoma study disappointment, and Ondas remains one of the most important drone-defense execution stories after record Q1 2026 revenue of $50.1 million, raised full-year 2026 revenue guidance of at least $390 million and backlog around $457 million. Biotech remains catalyst-heavy, with Cingulate’s May 31 PDUFA, Unicycive’s June 29 PDUFA, Capricor’s August 22 PDUFA, Zymeworks/Jazz’s August 25 zanidatamab date and INOVIO’s October 30 INO-3107 date keeping the FDA calendar active from late May through Q4 2026.

• NVDA— Nvidia remains the decisive AI event of the week, with traders watching whether data-center demand, Blackwell-cycle momentum and AI capex can defend the broader semiconductor leadership tradeAI Semis
• HD / LOW / TGT / WMT— Retail and housing-linked earnings become the main consumer test as Home Depot reports today, Lowe’s and Target follow, and Walmart later in the week checks spending resilienceRetail Macro
• NEE / D— NextEra’s $66.8 billion all-stock deal for Dominion puts AI power demand, data-center electricity needs and regulated utility scale directly into the market spotlightAI Power
• REGN— Regeneron remains under pressure after its fianlimab and Libtayo melanoma combination missed the main goal in a late-stage study, adding pipeline-execution risk to the healthcare tapeBiotech
• ONDS— Ondas remains the clearest drone-defense execution story after Q1 2026 revenue of $50.1 million, raised full-year revenue guidance of at least $390 million and backlog around $457 millionDrones
• LUNR— Intuitive Machines remains in post-earnings digestion after record quarterly revenue, positive adjusted EBITDA and record quarter-end backlog, but execution and revenue mix still matterSpace
• BEEM— Beam Global remains a “weak Q1 versus better Q2” recovery debate after low Q1 revenue, a larger backlog and management’s early-Q2 comment that revenue had already exceeded total Q1 salesEarnings
• UNCY— Unicycive remains one of the closest renal/metabolic FDA events, with the OLC NDA resubmission carrying a June 29, 2026 PDUFA target action datePDUFA
• CAPR— Capricor remains under FDA review for deramiocel with an August 22, 2026 PDUFA date, keeping labeling talks, manufacturing readiness and commercial preparation in focusPDUFA
• CING— Cingulate stays on the near-term FDA calendar with the May 31, 2026 PDUFA date for CTx-1301, while financing pressure and labeling risk remain part of the setupFDA

• Tuesday is calmer, not clean— Oil is easing from the worst fear levels, but futures remain soft and the market is still dealing with high energy prices, elevated yields and a crowded AI earnings tradeMarket
• Oil remains the macro variable— Brent near the $110 area and U.S. crude near the $107 area still keep inflation expectations sticky even if the immediate geopolitical panic has cooledOil
• Yields are still the pressure point— Treasury yields have steadied from the latest spike, but the level remains uncomfortable for biotech, speculative AI, clean energy, small-cap space and other duration-sensitive basketsRates
• Nvidia can reset the tape— NVDA earnings can either defend the AI leadership trade or trigger a broader valuation check across semiconductors, AI infrastructure, data-center power and cooling namesAI
• Retail earnings test real demand— HD, LOW, TGT, WMT, TJX and related names will be watched for traffic, ticket size, margin pressure, tariff/pass-through comments and housing-linked weaknessConsumer
• AI power demand is now a real theme— The NextEra-Dominion transaction reinforces that data-center electricity demand is not just a semiconductor story; utilities, grid assets and power infrastructure are now part of the AI tradePower
• Drone-defense momentum remains alive— ONDS, RCAT, KTOS, AVAV and KRMN remain tied to battlefield relevance, counter-UAS demand, funded orders and whether fast revenue growth can convert into margin qualityDefense
• Space stocks are still in execution mode— LUNR, RKLB, RDW, BKSY and PL are being judged on backlog quality, revenue conversion, cash discipline and whether headline contracts become durable revenueSpace
• PDUFA calendar stays crowded— CING, UNCY, CAPR, ZYME and INO keep FDA timing at the center of biotech trading as decision windows stretch from late May through Q4 2026FDA